FDAsafety guidance77% confidence
FDA AP — SUGAMMADEX SODIUM (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for RK Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA214368. Sponsor: MSN. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: SUGAMMADEX SODIUM.
Supporting Context
- Therapeutic area
- Immunology · Immunosuppressant
- Sub-indication
- General
Related signal: FDA Approval Status Update for Mycophenolate Sodium by RK Pharma